文献速递主动脉疾病

扩大腹主动脉瘤筛查的依据

The case for expanding abdominal aortic aneurysm screening.
PubMed 文献 · J Vasc Surg · 2019-12-09

美国预防服务工作组和英国国家卫生与临床优化研究所正在重新评估腹主动脉瘤筛查范式。当前多数国家仅筛查65至75岁男性吸烟者及有家族史者,但推荐主要基于血管内时代前的试验。血管内修复的广泛适用性和安全性改变了修复的风险获益,进而影响筛查。

要点

  • 当前筛查仅覆盖65-75岁男性吸烟者及有家族史者。
  • 现有推荐基于血管内时代前的筛查试验。
  • 血管内修复的安全性改变修复风险获益,支持扩大筛查。

核心结论

  • 血管内修复的广泛适用性和安全性改变了腹主动脉瘤修复的风险获益,支持重新评估并可能扩大筛查。

研究设计与样本

  • 本文为证据总结,批判性审视腹主动脉瘤筛查证据及扩大筛查的潜力。

主要发现

  • 当前筛查推荐主要基于血管内时代前的试验。
  • 血管内修复在老年患者中的安全性改变修复风险获益。
  • 尽管药物治疗改善和吸烟率下降使腹主动脉瘤患病率降低。

关键数值与推荐

  • 多数国家仅筛查65至75岁男性吸烟者及有家族史者。

临床怎么用

  • 临床应关注血管内修复时代对腹主动脉瘤筛查风险获益的重新评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Both the U.S. Preventive Services Task Force and the UK National Institute for Health and Care Excellence are re-evaluating their screening paradigms for abdominal aortic aneurysms (AAAs). Currently, most countries that screen for AAA do so only in male ever-smokers between the ages of 65 and 75 years and in patients with a family history of AAA. However, these recommendations are based primarily on screening trials predating the endovascular era. The wider applicability of endovascular aneurysm repair and its safety profile, especially in the elderly, have changed the risk-benefit of repair and, by extension, screening. This is despite the decreasing prevalence of AAA thanks to improved medical therapies and lower smoking rates. This evidence summary critically examines the evidence behind screening and the potential for expanded screening.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. O'Donnell TFX, Landon BE, Schermerhorn ML, et al. The case for expanding abdominal aortic aneurysm screening. J Vasc Surg. 2019. PMID: 31831309. doi:10.1016/j.jvs.2019.10.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。